Scarica l'app Stockscreener
4.57
57.04%
1.66
Dopo l'orario di chiusura:
4.73
0.16
+3.50%
Precedente Chiudi:
$2.91
Aprire:
$5.75
Volume 24 ore:
22.97M
Relative Volume:
55.51
Capitalizzazione di mercato:
$39.95M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-6.4439
EPS:
-0.7092
Flusso di cassa netto:
-
1 W Prestazione:
+36.83%
1M Prestazione:
+30.57%
6M Prestazione:
+178.66%
1 anno Prestazione:
+101.32%
Intervallo 1D:
$4.07
$5.87
Intervallo di 1 settimana:
$2.76
$5.87
Portata 52W:
$1.001
$5.87
Alterity Therapeutics Ltd Adr Stock (ATHE) Company Profile
Nome
Alterity Therapeutics Ltd Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta ATHE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATHE
Alterity Therapeutics Ltd Adr
|
4.57 | 39.95M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Alterity Therapeutics Ltd Adr Stock (ATHE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-12 | Iniziato | Maxim Group | Buy |
Alterity Therapeutics Ltd Adr Borsa (ATHE) Ultime notizie
Alterity Therapeutics announces ATH434 Phase 2 trial results - MSN
Alterity Therapeutics Reports Promising Phase 2 Results for MSA Drug ATH434 - TipRanks
Alterity Therapeutics announces trading halt - Investing.com
Alterity Therapeutics Initiates Trading Halt Pending Phase II Trial Results - TipRanks
Alterity Therapeutics reports quarterly activities - Investing.com
Alterity Therapeutics reports quarterly activities By Investing.com - Investing.com UK
Alterity Therapeutics Advances ATH434 Clinical Trials with Promising Data - TipRanks
Alterity Therapeutics Reports Key Advances and Anticipates Milestones in 2025 - TipRanks
Opthea reports positive Phase 1b DME trial results - Investing.com
ASX November Health Winners: Paradigm, Imricor lead sector as momentum returns - Stockhead
Alterity Therapeutics reports annual general meeting results By Investing.com - Investing.com South Africa
Alterity Therapeutics reports annual general meeting results - Investing.com India
Alterity Therapeutics announces change in company secretary - Investing.com
Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary - Yahoo Finance
Opthea adds Kathy Connell to Board of Directors - Investing.com
Alterity Therapeutics to join Maxim Healthcare Summit - Investing.com
Tau Inhibitors Clinical Trial Pipeline Analysis Demonstrates 25+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
Alterity Therapeutics announces change in share registry - Investing.com
Alterity Therapeutics announces change in share registry By Investing.com - Investing.com UK
Opthea Ltd stock soars to 52-week high, hits $4.47 - Investing.com India
Alterity Therapeutics names new CFO - Investing.com India
Alterity Therapeutics discloses annual report for 2024 - Investing.com
ATHEAlterity Therapeutics Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Check Up: Aussie biotech Avarax on the verge of peanut allergy cure; and recent ASX health winners - Stockhead
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money ... - Stockhead
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) - PR Newswire
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection - Yahoo Finance
The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger - Yahoo Finance
Alterity Therapeutics Ltd Adr Azioni (ATHE) Dati Finanziari
Non sono disponibili dati finanziari per Alterity Therapeutics Ltd Adr (ATHE). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
5.49%
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):